MICA*012:01Allele Facilitates the Metastasis of KRAS-Mutant Colorectal Cancer

被引:9
|
作者
Ding, Weifeng [1 ,2 ]
Ma, Yanyun [3 ]
Zhu, Weifeng [4 ]
Pu, Weilin [3 ]
Zhang, Jianfeng [5 ]
Qian, Fei [6 ]
Zhou, Youlang [7 ]
Deng, Yan [8 ]
Guo, Shicheng [9 ]
Wang, Jiucun [3 ,10 ,11 ]
Zhou, Xiaodong [2 ]
机构
[1] Nantong Univ, Dept Lab Med, Affiliated Hosp, Nantong, Peoples R China
[2] Univ Texas Houston, McGovern Med Sch, Houston, TX 77030 USA
[3] Fudan Univ, Collaborat Innovat Ctr Genet & Dev, Sch Life Sci, State Key Lab Genet Engn, Shanghai, Peoples R China
[4] Nanchang Univ, Coll Basic Med Sci, Dept Biochem & Mol Biol, Nanchang, Jiangxi, Peoples R China
[5] Nantong Univ, Dept Gastroenterol, Affiliated Hosp, Nantong, Peoples R China
[6] Nantong Univ, Dept Gastrointestinal Surg, Affiliated Hosp, Nantong, Peoples R China
[7] Nantong Univ, Hand Surg Res Ctr, Dept Hand Surg, Affiliated Hosp, Nantong, Peoples R China
[8] Nanchang Univ, Dept Ophthalmol Children, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China
[9] Marshfield Clin Fdn Med Res & Educ, Ctr Precis Med Res, Res Inst, Marshfield, WI USA
[10] Fudan Univ, Inst Rheumatol Immunol & Allergy, Shanghai, Peoples R China
[11] Fudan Univ, Human Phenome Inst, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
MICA polymorphism; colorectal cancer; MICA*012; 01allele; immunosurveillance; tumor immunity; E-CADHERIN; MICA; NKG2D; OVEREXPRESSION; SUSCEPTIBILITY; POLYMORPHISM; STATISTICS; EXPRESSION; DISEASE; TUMOR;
D O I
10.3389/fgene.2020.00511
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Major histocompatibility complex (HLA) class I chain-related protein A (MICA) regulates immune surveillance through activation of NKG2D (natural killer group 2D) receptor. However, the genetic association, potential function, and predictive ability of MICA alleles with colorectal cancer (CRC) prognosis remain undefined. In this study, we characterized MICA alleles in tissue samples from 104 patients with CRC and 536 healthy controls and carried out genetic association studies by molecular and clinical CRC phenotypes. Preliminary sequence analysis revealed thatMICA*009:01or*049alleles were significantly decreased in patients with CRC (p= 0.0049), and further stratification analysis indicated thatMICA*012:01allele was associated with patients with CRC and carrying KRAS codon 12 mutation (p= 0.027). The functional consequences of MICA alleles were examined via transfected CRC cell lines which showed that overexpression ofMICA*012:01enhanced the proliferation, invasion, and metastatic phenotype of CRC. Preliminary analysis of disease-free survival time in patients with and withoutMICA*012:01suggest this allele may be predictive for poor prognosis of patients with KRAS codon 12 mutated CRC, as no somatic mutation of MICA gene was detected in CRC tumors compared to paracancerous tissues. Our study indicates thatMICA*012:01allele is associated with KRAS-mutated CRC, facilitates CRC invasion and metastasis, and possibly reduces the survival of patients with KRAS-mutated CRC.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Correction: Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer
    Steve Wagner
    Georgios Vlachogiannis
    Alexis De Haven Brandon
    Melanie Valenti
    Gary Box
    Liam Jenkins
    Caterina Mancusi
    Annette Self
    Floriana Manodoro
    Ioannis Assiotis
    Penny Robinson
    Ritika Chauhan
    Alistair G. Rust
    Nik Matthews
    Kate Eason
    Khurum Khan
    Naureen Starling
    David Cunningham
    Anguraj Sadanandam
    Clare M. Isacke
    Vladimir Kirkin
    Nicola Valeri
    Steven R. Whittaker
    Oncogene, 2019, 38 : 5746 - 5746
  • [42] MET inhibition radiosensitizes KRAS-mutant rectal cancer.
    D'Ambrosio, Antonio
    Verginelli, Federica
    Orzan, Francesca
    Albano, Raffaella
    Casanova, Elena
    Luraghi, Paolo
    De Bacco, Francesca
    Bertotti, Andrea
    Trusolino, Livio
    Senetta, Rebecca
    Sapino, Anna
    Del Mastro, Elena
    Gatti, Marco
    Comoglio, Paolo M.
    Boccaccio, Carla
    CANCER RESEARCH, 2021, 81 (13)
  • [43] A novel combination strategy to treat KRAS-mutant lung cancer
    Peng, R. -W.
    Liang, S. -Q.
    Buhrer, E. D.
    Berezowska, S.
    Marti, T. M.
    Froment, L.
    Yang, H.
    Hall, S. R.
    Vassella, E.
    Yang, Z.
    Kocher, G. J.
    Amrein, M. J.
    Riether, C.
    Ochsenbein, A. F.
    Schmid, R. A.
    BRITISH JOURNAL OF SURGERY, 2019, 106 : 19 - 19
  • [44] Immunogenic chemotherapy effectively constrains KRAS-mutant lung cancer
    Wang, D.
    Cong, J.
    Fu, B.
    Zheng, X.
    Sun, R.
    Tian, Z.
    Wei, H.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1893 - 1893
  • [45] Development of SOS1 Inhibitor-Based Degraders to Target KRAS-Mutant Colorectal Cancer
    Bian, Yujia
    Alem, Diego
    Beato, Francisca
    Hogenson, Tara L.
    Yang, Xinrui
    Jiang, Kun
    Cai, Jianfeng
    Ma, Wen Wee
    Fernandez-Zapico, Martin
    Tan, Aik Choon
    Lawrence, Nicholas J.
    Fleming, Jason B.
    Yuan, Yu
    Xie, Hao
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (24) : 16432 - 16450
  • [46] Novel Polymethoxylated Chalcones as Potential Compounds Against KRAS-Mutant Colorectal Cancers
    Mahmoud, Alaa
    Elkhalifa, Dana
    Alali, Feras
    Al Moustafa, Ala-Eddin
    Khalil, Ashraf
    CURRENT PHARMACEUTICAL DESIGN, 2020, 26 (14) : 1622 - 1633
  • [47] Effect of RAD21 overexpression on prognosis in KRAS-mutant colorectal carcinomas
    Silva, Thomaz De Campos
    Deb, Siddhartha
    Xu, Huiling
    Yan, Yuqian
    Fox, Stephen B.
    Mortensen, Neil
    McKay, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [48] An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo
    Tomoshige, Koichi
    Guo, Minzhe
    Tsuchiya, Tomoshi
    Fukazawa, Takuya
    Fink-Baldauf, Iris M.
    Stuart, William D.
    Naomoto, Yoshio
    Nagayasu, Takeshi
    Maeda, Yutaka
    ONCOGENE, 2018, 37 (28) : 3894 - 3908
  • [49] The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancer
    Wong, Chi Chun
    Wu, Jian-Lin
    Ji, Fenfen
    Kang, Wei
    Bian, Xiqing
    Chen, Huarong
    Chan, Lam-Shing
    Luk, Simson Tsz Yat
    Tong, Samuel
    Xu, Jiaying
    Zhou, Qiming
    Liu, Dabin
    Su, Hao
    Gou, Hongyan
    Cheung, Alvin Ho-Kwan
    To, Ka Fai
    Cai, Zongwei
    Shay, Jerry W.
    Yu, Jun
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [50] Reduced replication origin licensing selectively kills KRAS-mutant colorectal cancer cells via mitotic catastrophe
    Gastl, Bastian
    Klotz-Noack, Kathleen
    Klinger, Bertram
    Ispasanie, Sylvia
    Salib, Krenoula Hani Fouad
    Zuber, Johannes
    Mamlouk, Soulafa
    Bublitz, Natalie
    Bluethgen, Nils
    Horst, David
    Morkel, Markus
    Schaefer, Reinhold
    Sers, Christine
    CELL DEATH & DISEASE, 2020, 11 (07)